125 results about "Anticarcinogen" patented technology

The present disclosure describes methods comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition and a therapeutically-effective amount of an anti-cancer agent. The disclosed methods can comprise administering a pharmaceutical composition comprising a short chain fatty acid or a pharmaceutically-acceptable salt or ester thereof. The disclosed methods can be used to treat a cancer.

METHODS OF TREATING CANCER BY ADMINISTERING MCL-1 INHIBITORS AND ANTI-CANCER AGENTS SOLUTION: The present disclosure relates generally to methods for treating cancer by administering an MCL-1 inhibitor and an anti-cancer agent. As is explained in detail in the present specification and as is specifically demonstrated, according to the present invention, a remarkable effect is achieved, which could not be easily expected by those skilled in the art from the prior art.SELECTED DRAWING: Figure 5

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

The present invention relates to a PROTAC compound which can increase the degradation effect of a protein of interest, and to a novel piperidinedione compound which can be used as an E3 enzyme ligand of the PROTAC compound. The piperazinedione derivative compound of the present invention acts on CRBN and thus may be used as a therapeutic agent (for example, an anticancer agent or an immunomodulator) for diseases associated with CRBN proteins.

Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

The present application provides compounds of Formula (I), or a stereoisomer thereof, or a atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of a atropisomer thereof; methods of making the compounds and therapeutic uses thereof. The present application further provides combinations of pharmacologically active agents and pharmaceutical compositions comprising the compounds.

The present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and at least one anti-cancer agent. It also relates to a process of preparing the composition and a method / use of the peptide alone or in combination with at least one anti-cancer agent in preventing or managing or treating cancer / precancerous condition.

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

As used herein, the formula (I) [Formula 1] JPEG2025535263000074.jpg6899 or a pharmaceutically acceptable salt thereof, wherein the variables of formula (I) are as defined herein. Such compounds may be useful as anti-cancer agents.

The present invention relates to pyrazolyl derivatives useful as anticancer agents. More specifically, the present invention provides pyrazolyl derivative compounds; the use thereof for inhibiting KRAS G12C, HRAS G12C or NRAS G12C, and in particular KRAS G12C; methods of treating or preventing diseases, particularly cancer, using the compounds; and processes and intermediates for preparing these compounds. The invention also provides these pyrazolyl derivative compounds for use in the treatment of cancer and specific cancers as defined herein.

A method of inhibiting cell growth in a cancer includes contacting a graphite-phase carbon nitride copper oxide and magnesium aluminum oxide (g-C3N4@CuO / MgAl2O4) nanocomposite with the cancer to inhibit growth of the cancer. The g-C3N4@CuO / MgAl2O4 nanocomposite comprises a graphite-phase carbon nitride (g-C3N4) in an amount of 2 to 18 percent by weight (wt. %), copper oxide in an amount of 1 to 10 wt. %, and magnesium aluminum oxide (MgAl2O4) in an amount of 75 to 95 wt. % based on a total weight of the g-C3N4@CuO / MgAl2O4 nanocomposite. The cancer includes cells from a cell line selected from a group consisting of a human hepatocellular carcinoma (HepG-2) cell line and a human breast carcinoma (MCF-7) cell line.

To provide a composition for delivering a nucleic acid capable of delivering the nucleic acid into a cell and obtaining the function of the nucleic acid.SOLUTION: The composition for delivering a nucleic acid comprises a fine particle containing a polyamino acid and a nucleic acid held by the fine particle.SELECTED DRAWING: Figure 1

The compound according to the present invention exhibits excellent anticancer effects against the triple-negative breast cancer cell line MDA-MB-231 and liver cancer cell lines as well as general cancer cell lines such as A549, SK-OV-3, SK-MEL-2, HCT15, etc., and thus can be advantageously used as an anticancer agent.

The present invention relates to a pharmaceutical composition comprising an aryl piperidine derivative compound or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tankyrase-related cancer diseases. The pharmaceutical composition inhibits the enzymatic activity of tankyrase (TNKS), inhibits the expression of a beta-catenin target gene and the protein expression of active beta-catenin, stabilizes AXIN2 protein levels, and exhibits anti-cancer activity in a cancer cell line, so that the compound can be used as an anti-cancer agent, in particular as an anti-cancer agent. And elicits synergistic effects in combination therapy with other anti-cancer agents.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

The present invention relates to a novel CRS fragment peptide with immune-enhancing activity and its uses, more specifically to a novel peptide consisting of the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having 95% or more sequence homology thereto, and its use as a vaccine adjuvant, an anticancer agent, and an antiviral composition. The peptide disclosed in the present invention is a CRS fragment disclosed for the first time in this specification, exhibiting anticancer activity, immune function enhancement, and antiviral activity.

The present application relates to a pharmaceutical composition for inhibiting anticancer agent resistance, restoring anticancer agent responsiveness, or enhancing anticancer agent sensitivity, comprising an ODC1 inhibitor as an effective ingredient. Specifically, when EGFR-targeted therapeutic agent resistance was induced using a non-small cell lung cancer cell model in which kinase overexpression is involved and a xenotransplantation animal model thereof, it was confirmed that if ODC1 expression or activity is inhibited, the acquisition of EGFR-targeted therapeutic agent resistance caused by kinase overexpression is inhibited, and the resistance is alleviated, thereby exhibiting an effect of restoring drug responsiveness. Therefore, a preparation that inhibits the expression or activity of the ODC1 can be effectively used as an effective ingredient of a pharmaceutical composition for inhibiting anticancer agent resistance, restoring anticancer agent responsiveness, or enhancing anticancer agent sensitivity.

Provided herein are methods and formulations for reducing viability of a cancer or enhancing susceptibility of a cancer to an anti-cancer agent. The method includes administering to the subject an effective amount of an anti-parasitic agent and an autophagy inhibitor to the subject. Additionally or optionally, the method further includes administering to the subject the anti-cancer agent. Also provided herein are formulations for the treatment of cancers, particularly cancers that are unresponsive to anti-cancer agents. The formulation includes at least two agents selected from the group consisting of an anti-parasitic agent, an autophagy inhibitor and an HDAC inhibitor; and a pharmaceutically acceptable excipient.

Disclosed herein are conjugates comprising an alpha particle emitter and an anti-cancer agent, compositions comprising the conjugate, kits for radiolabeling with an alpha particle emitter and an anti-cancer agent, and a method of using the conjugate to treat cancer. The alpha-particle emitter and the anti-cancer agent may be unmodified or linked to each other with a chelating agent.

An anticancer agent is provided comprising, as active ingredients, NK cells and a fusion protein comprising an IL-2 protein and a CD80 protein. In one specific formulation, a fusion protein comprising a CD80 fragment, an immunoglobulin Fc region, and an IL-2 variant can activate immune cells such as natural killer cells. Furthermore, since the pharmaceutical composition can effectively inhibit cancer, when co-administered with natural killer cells, it increases immune activity in the body, making it effective for cancer treatment and thus highly applicable to industry.

Disclosed is a compound of formula (I): or a stereoisomer, tautomer or salt thereof. Also disclosed are methods of using such compounds to reduce the level of the IKZF1-4 protein; and a pharmaceutical composition comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer. (I)

The invention provides an isoalantolactone derivative TYJ2517, namely 3, 4, 5-trimethoxybenzyl aminomethyl 3-demethyleneisoalantolactone as well as preparation and application thereof, and relates to the field of medicinal compounds, the structure of the isoalantolactone derivative is shown as follows: although many anti-cancer drugs have anti-cancer ability, the drugs generate toxicity to normal cells, and the drugs cannot generate toxicity to the normal cells. Therefore, the development of selective anti-cancer active drugs safe to normal cells is particularly important. According to the invention, TYJ2517 is synthesized, the IC50 value of the TYJ2517 to MCF-7 cells is 3.6 + / -0.8 [mu] M, and the IC50 value of the TYJ2517 to L-02 normal cells exceeds 100 [mu] M. A cell drug uptake capability test result shows that the TYJ2517 uptake capability of L-02 normal cells is low, and the TYJ2517 uptake capability of MCF-7 cancer cells is high. When the administration time is 1 hour, the selective anti-cancer index (SI) of the TYJ2517 to MCF-7 breast cancer cells and L-02 normal cells exceeds 40. Mechanism research shows that the activity of the TYJ2517 for resisting MCF-7 cancer cells is a result of inhibiting the expression quantity of PARP1 protein kinase and ROS, inducing early and late apoptosis of the MCF-7 cells and hindering migration and colony of the MCF-7 cells.

The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents

Described herein are methods for reducing or preventing blood flow in a neurovascular blood vessel of a subject. The method involves injecting a composition composed of water, one or more polycationic polyelectrolytes and anionic counterions, one or more one polyanionic polyelectrolytes and cationic counterions, and a statin, an anti-cancer agent, or a combination thereof, wherein the composition has an ion concentration that is (i) sufficient to prevent association of the polycationic polyelectrolytes and the polyanionic polyelectrolytes in water and (ii) greater than the concentration of ions in the subject. Upon introduction of the composition into a subject, a solid is produced in situ. The injectable compositions have unique distal penetration properties, which make the injectable compositions described herein very useful as embolics for neurovascular blood vessels.

The present disclosure provides polypeptide constructs that, when exposed to sufficient levels of ATP, cause them to assemble into dimers or higher order complexes (e.g., trimers, tetramers, etc.), thereby acting as immune cell function agonists. The constructs can also be conjugated to one or more therapeutic, chemotherapeutic, or labeling agents. The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cells and / or NK cells) that function to promote an anti-tumor immune response, and delivering the conjugated agent to the tumor microenvironment. The constructs can be used as anti-cancer / therapeutic agents for the treatment of solid tumors with elevated ATP levels.

The disclosure provides a fusion polypeptide specific for CD137 and GPC3, which fusion polypeptide may be useful for directing CD137 clustering and activation of GPC3-positive cancer cells. Such a fusion polypeptide may be useful in many pharmaceutical applications, for example, as an anticancer agent and / or immunomodulator for the treatment or prevention of human diseases, such as a variety of cancers. The disclosure also relates to methods of making the fusion polypeptide described herein, as well as compositions comprising such a fusion polypeptide. The disclosure further relates to nucleic acid molecules encoding such a fusion and nucleic acid molecules. Furthermore, the disclosure includes therapeutic and / or diagnostic uses of such a fusion polypeptide, as well as compositions comprising one or more such fusion polypeptides.

EphA2 targeting agents developed herein are potent peptide-mimetics with high affinity (Kds 8-20 nanomolar) for the ligand binding domain, called targefrin. Monomeric versions of targefrin act as antagonists while dimeric versions (targefrin-dimer) of the agent cause receptor internalization and degradation via a lysosomal pathway. Hence, targefrin-dimer agents are effective in reducing pro-oncogenic EphA2 levels in cancer cells when used as single agents or in combination with standards of care. Targefrin-dimers can also sensitive cancer cells that developed resistance to EGER or BRAE inhibitors, and potentially other anti-cancer agents. In addition, the dimeric agents can be conjugated with chemotherapy such as paclitaxel to deliver selectively cytotoxic agent to EphA2 expressing cancer cells. Monomeric agents can be linked to chemotherapy via a stable cleavable linker, accumulate the cytotoxic at the tumor, that then would enter the tumor. Novel composition and examples of these applications are reported.